![PXP Energy Corporation (GM)](/common/images/company/NO_PXPEF.png)
PXP Energy Corporation (GM) (PXPEF)
USOTC
Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study MT-601 was well tolerated with no observation of...
HOUSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies...
Preliminary data from study in patients with lymphoma enrolled at City of Hope National Medical Center was presented at the 11th Global Summit on Hematologic Malignancies in Whistler, BC, Canada...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0.05 | 0.05 | 0.05 | 1785 | 0.05 | CS |
26 | 0 | 0 | 0.05 | 0.05 | 0.05 | 1785 | 0.05 | CS |
52 | 0 | 0 | 0.05 | 0.05 | 0.05 | 1785 | 0.05 | CS |
156 | -0.06 | -54.5454545455 | 0.11 | 0.11 | 0.05 | 609 | 0.07664947 | CS |
260 | -0.22 | -81.4814814815 | 0.27 | 0.27 | 0.05 | 1646 | 0.11887728 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.